Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition

Sponsor
Florida State University (Other)
Overall Status
Completed
CT.gov ID
NCT02143817
Collaborator
NOW Foods (Other)
60
1
4
10.1
6

Study Details

Study Description

Brief Summary

Arterial dysfunction contributes to the development of cardiovascular disease (CVD), which is currently afflicting millions of individuals. The use of the amino acid L-citrulline has been suggested as a potential aid for the treatment of CVD by increasing endothelial production of Nitric Oxide (NO). Whole body vibration (WBV) is new and effective form of exercise that is feasible for clinical populations and has been proven to decrease blood pressure (BP) and arterial stiffness and increase muscle mass and strength. Therefore, the purpose of this study was to investigate if the combination of WBV training (WBVT) plus L-citrulline supplementation would induce positive additive effects and would be an effective means to ameliorate arterial stiffness, endothelial function, BP and muscle strength/mass in postmenopausal women.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: L-citrulline supplementation
  • Other: Whole Body Vibration Training
N/A

Detailed Description

The purpose of this study is to investigate the effects of 8 weeks combination of WBVT plus L-citrulline supplementation on arterial stiffness, endothelial function, BP and muscle strength/mass in overweight/obese postmenopausal women.

The specific aims of the study are:
  1. To investigate if the additive effect of 8 weeks of WBVT combined with L-citrulline supplementation are more efficacious than either treatment alone in ameliorating cardiovascular disease risk factors by assessing arterial stiffness (aortic, systemic, and leg), aortic BP and wave reflection, and autonomic function (heart rate variability, vascular sympathetic activity [low-frequency power of systolic BP variability], and baroreflex sensitivity). Flow mediated dilation and circulating levels of adipocytokines (adiponectin and leptin) and endothelial-derived vasodilators (NO metabolites [NOx], 6-keto PGFIa, insulin, and ghrelin) and vasoconstrictors (endothelin-1 [ET-1],8-iso PGF2a,vascular endothelium growth factor [VGEF]) will be assessed as secondary outcome variables.

  2. To evaluate the extent to which 8 weeks of WBVT combined with L-citrulline improves body composition assessed by changes in fat mass and lean mass using dual-energy x-ray absorptiometry and waist circumference.

  3. To determine the additive effect of 8 weeks of WBVT combined with L-citrulline supplementation on muscle strength. These will be evaluated using the eight-repetition maximum test for the leg press and chest press exercises

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Basic Science
Official Title:
The Effect of Whole-body Vibration Training Combined With L-cit Supplementation on Cardiovascular, Autonomic Function and Body Composition in Postmenopausal Women
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Jan 1, 2014
Actual Study Completion Date :
Jan 1, 2014

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.

Experimental: Whole body vibration training plus L-citrulline

Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)

Dietary Supplement: L-citrulline supplementation
Other Names:
  • 8 weeks of L-citrulline supplementation in two doses of 3g each per day (6g per day)
  • Other: Whole Body Vibration Training
    The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).

    Experimental: Whole body vibration training & placebo

    Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)

    Other: Whole Body Vibration Training
    The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).

    Experimental: L-citrulline supplementation

    (6g per day)containing L-citrulline

    Dietary Supplement: L-citrulline supplementation
    Other Names:
  • 8 weeks of L-citrulline supplementation in two doses of 3g each per day (6g per day)
  • Outcome Measures

    Primary Outcome Measures

    1. Blood Pressure [8 weeks]

      Non-invasive measures of brachial and aortic blood pressure

    2. Arterial Stiffness and pressure wave reflection [8 weeks]

      Using pulse wave velocity of the aorta, systemic, and legs and the augmentation index from radial tonometry

    3. Endothelial and autonomic functions [8 weeks]

      By measuring circulating levels of adipocytokines (adiponectin and leptin) and endothelial-derived vasodilators (NOx, 6-keto PGFIa, insulin, and ghrelin)and vasoconstrictors (ET-1 and 8-iso PGF2a, VEGF).In addition, heart rate variability, vascular sympathetic activity [low-frequency power of systolic BP variability], and spontaneous baroreflex sensitivity will be assessed from electrocardiogram and beat-by-beat digital blood pressure.

    Secondary Outcome Measures

    1. Body Composition [8 weeks]

      By measuring fat mass and lean soft tissue mass from dual-energy x-ray absorptiometry and waist circumference

    2. Muscle Strength [8 weeks]

      Using eight-repetition maximum (8-RM) test for the leg press and chest press exercises

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 70 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Female 50 to 70 years of age At least 1 year after menopause Body mass index of 27-39.9 Sedentary or low active (less than 2 hr per wk)

    Exclusion Criteria:

    Younger than 50 or older than 70 years of age Body mass index lower than 27, or 40 or higher Physically active or competitively active Smoker Use of hormone replacement therapy of less than 1 yr Use of calcium channel blocker or beta blockers Use dietary supplementations (e.g.,L-arginine,L-citrulline,antioxidants) Uncontrolled diabetes Any restriction that would significantly interfere with compliance with the L-citrulline supplementation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 FSU College of Human Sciences Tallahassee Florida United States 32306

    Sponsors and Collaborators

    • Florida State University
    • NOW Foods

    Investigators

    • Principal Investigator: Alexei Wong, Florida State University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Arturo Figueroa, Associate Professor, Florida State University
    ClinicalTrials.gov Identifier:
    NCT02143817
    Other Study ID Numbers:
    • HSC2012.9674
    First Posted:
    May 21, 2014
    Last Update Posted:
    Mar 10, 2015
    Last Verified:
    Mar 1, 2015
    Keywords provided by Arturo Figueroa, Associate Professor, Florida State University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 10, 2015